Please log in
to access more information

loading...

User name and Password not recognised

Home Page > News > Diary Dates

OFFICIAL LAUNCH OF HEMOBLAST™ BELLOWS IN SPAIN

Today, Thursday January 24th, Biom’up and Palex have launched Hemoblast Bellows into the Spanish market at a kick-off meeting in Barcelona (Spain). All surgical sales and marketing  staff  of Palex Medical were educated on HEMOBLAST Bellows, a hemostatic powder to control bleeding in a broad range of both traditional and laparoscopic surgical procedures, such as cardiac, general and orthopedic surgeries, and give patients a better quality of life.

The session included hands-on application of Hemoblast Bellows by every participant, an expert round table on its benefits in Cardio-thoracic, spine and laparoscopic surgeries, as well as clinical data and commercial discussions.   

Carlos Chordá, General Manager of Palex Medical, a leading medical device distributor in the Iberian Peninsula, based in Barcelona and Madrid, opened the session with his team emphasizing the broad range of indications that Hemoblast Bellows will be used in. The program was led by Prof. William Spotnitz, Biom’up Chief Medical Officer in collaboration with key  surgeons who are using HEMOBLAST Bellows successfully in their surgical routine  and clinical trials, Dr. Thierry Barthes (Abdominal and Laparoscopic Surgeon, Polyclinic of Poitiers, France), Dr. Pierre-Marie Longis (Spine Surgeon, Private Hospital of Confluent, Nantes, France) and Dr. Alexandros Paraforos (Chief Consultant and Deputy Medical Director, Department of Cardio-Thoracic Surgery, Trier, Germany).

Prof. William Spotnitz comments on the session: « Wonderfully informative, innovative, and cooperative meeting, with a lot of interaction and helpful discussion ».

Through its comprehensive sales network covering Spain’s main hospitals, Palex will contribute to an important commercial breakthrough for Biom’up. The Spanish market for topical hemostats is one of the largest in the European Union, estimated to have reached €75m and growing at 5% annually (source: Grand View Research)